Abstract
[10B]Boronophenylalanine (10B-BPA) has been used as a tumor selective boron carrier for boron neutron capture therapy (BNCT) in the treatment of malignant melanoma1. In the same way, it is thought to be a potential boron carrier for the treatment of malignant glioma2–4. Glioma infiltrates peripheral brain tissue and we always fall into the dilemma between resection and preservation of the infiltrated brain. Thus the treatment will be effective in these infiltrative tumors. In our studies of malignant glioma using positron emission tomography (PET), accumulation of 10B-BPA analog, [18F]fluoroboronophenylalanine (18F-10B-FBPA), in tumor lesion was dramatically revealed3. The metabolic analysis of this positron-emitting analog demonstrated that enhancement of the amino acid transport is a primary factor for the high accumulation3,5. [18F]Fluoroboronophenylalanine has been recognized as a compound that is incorporated into tumor cell selectively.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Y. Mishima, C. Honda, M. Ichihashi, H. Obara, J. Hiratsuka, H. Fukuda, I1. Karashima, T. Kobayashi, K. Kanda and Y. Yoshino, Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B-Compound. Lancet 11: 388–389, 1989.
J. A. Coderre, D.D.Joel, P.L. Micca, M.M. Nawrocky, D.N.Slatkin, Control ofintracerchra1 gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiation Research 129: 290296, 1992.
S. Ueda, Y. Imahori, N. lbayashi, Y. Ohmori, K. Ono, T. Kobayashi, K. Akuta, The basic studies for boron neutron capture therapy (BNCT) of brain tumor using boronophenylalaninc. KURRI Prog. Rep. (Osaka): 304–305, 1992.
Y. Imahori, S. Ueda, N. lbayashi, Y. Ohmori, Metabolic evaluation of malignant brain tumor using ‘8F–10BPA by positron emission tomography to determine the feasibility of boron neutron therapy [abstract]. International Congress of Radiation Oncology: 285, 1993.
Y. Mishima, Y. Imahori, C. Honda, S. Ueda, T. Ido, In vivo diagnosis of human malignant melanoma using specific melanoma-seeking 18F-compound with positron emission tomography. Kyoto University Research Reactor Institute - Technical Report - (Osaka) 374,1–10, 1993.
Y. Mishima, Investigation for the extended application of melanoma boron neutron capture therapy. Kyoto University Research Reactor Institute–Technical Report- (Osaka) 356, 192–199, 1991.
S. Ueda, Y. Imahori, Y. Ohmori, E. Yoshino, K. Ono, T. Kobayashi, M. Takagaki, Y. Oda, T. Ido, Y. Mishima, Positron emission tomography and boron neutron capture therapy system to the patient with brain tumor -The first clinical trial using BPA-. In: Cancer Neutron Capture Therapy, Y. Mishima, ed., pp. 823–828 Plenum, New York, 1996.
S. C. Huang, M. E. Phelps, E. J. Hoffman, K. Sideris, C. J. Sel in, D. E. Kuhl, Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238: E69 - E82, 1980.
K. Ishiwata, M. Shiono, K. Kubota, K. Yoshino, J. Hatazawa, T. Ido, C. Monda, M. Ichihashi and Y. Mishima, A unique in vivo assessment of 4-[’°B]borono-L-phenylalanine in tumor tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2[1sF]fluoro-L-phenylalaniIle. Melanoma Res. 2: 171–179, 1992.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Imahori, Y. et al. (1996). A Basic Concept for PET-BNCT System. In: Mishima, Y. (eds) Cancer Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9567-7_99
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9567-7_99
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9569-1
Online ISBN: 978-1-4757-9567-7
eBook Packages: Springer Book Archive